Regeneron Pharmaceuticals announced that the FDA accepted its resubmitted Biologics License Application (BLA) for odronextamab. The drug is intended to treat relapsed/refractory follicular lymphoma (FL) after patients have undergone at least two other systemic therapies. The FDA is expected to make a decision by July 30, 2025.
This resubmission is a critical step for Regeneron and potentially for patients battling this incurable cancer. The FDA’s acceptance signifies that Regeneron has successfully addressed the previous approvability issue related to patient enrollment in the confirmatory Phase 3 trial. A potential approval could provide a new treatment option for patients who have limited alternatives after multiple rounds of therapy, potentially improving their outcomes. It also strengthens Regeneron’s position in the hematology-oncology market.
The resubmitted BLA includes data from Phase 1 and pivotal Phase 2 trials, which showed an 80% overall response rate and a 74% complete response rate. However, serious adverse events were observed in 67% of patients, with cytokine release syndrome, COVID-19, and pneumonia occurring in a notable percentage. Odronextamab is already approved in the European Union for relapsed/refractory FL and diffuse large B-cell lymphomaB-cell lymphoma, offering a glimpse into its potential market reach.
The FDA decision regarding odronextamab will be a defining moment. A positive outcome would mark a significant advancement in the treatment of relapsed/refractory FL and could lead to increased market share for Regeneron. Conversely, a rejection would likely delay the drug’s availability in the U.S. and potentially impact future development strategies. The outcome will undoubtedly influence the landscape of FL treatment and shape Regeneron’s trajectory in the hematology-oncology field.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
